InvestorsHub Logo
Followers 82
Posts 3648
Boards Moderated 0
Alias Born 02/15/2010

Re: rocalinda post# 69601

Sunday, 07/24/2016 4:24:05 PM

Sunday, July 24, 2016 4:24:05 PM

Post# of 458423
A2-73 alone is only being dosed in 7 patients. Anavex may well decide to proceed into the next trial with what they have the most info on. That is A2-73 and donepezil.

Also, Caufield Hospital posted info on AVXL's next trial. Included in that info was a statement that all potential patients needed to be taking donepezil. A link to this was posted here. I wish the poster would post it again.

IF Anavex proceeds with A2-73 and donepezil, then the Anavex patent application, that, if grahted, would expire in 2033, becomes very important to the Company.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News